Image guided dose escalated prostate radiotherapy: Still room to improve

Radiation Oncology

Volumn 4, Issue 1, 2009, Pages 50-

  Martin, Jarad M ^a,b   Bayley, Andrew ^a   Bristow, Robert ^a   Chung, Peter ^a   Gospodarowicz, Mary ^a   Menard, Cynthia ^a   Milosevic, Michael ^a   Rosewall, Tara ^a   Warde, Padraig R ^a   Catton, Charles N ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b ROYAL BRISBANE AND WOMEN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIANDROGEN;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER GRADING; CANCER HORMONE THERAPY; CANCER INCIDENCE; COMPUTER ASSISTED RADIOTHERAPY; CONTROLLED STUDY; GASTROINTESTINAL TOXICITY; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PHOTODYNAMIC THERAPY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE SURGERY; RADIATION DOSE; RISK ASSESSMENT;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DIAGNOSTIC IMAGING; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; RADIOTHERAPY, CONFORMAL; RADIOTHERAPY, INTENSITY-MODULATED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 70849090938     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-4-50     Document Type: Article

References (40)

1. Ferlay J, Bray F, Pisani P, Parkin D. Globocan 2002: Cancer Incidence, Mortality and Prevalence Worldwide. Lyon [updated 2004; cited April 24, 2006]; IARC CancerBase No. 5. version 2.0., http://www-dep.iarc.fr/
2. Bolla M, Collette L, Blank L, Warde P, Dubois JB, Mirimanoff RO, Storme G, Bernier J, Kuten A, Sternberg C, Mattelaer J, Lopez Torecilla J, Pfeffer JR, Lino Cutajar C, Zurlo A, Pierart M. Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial. Lancet 2002, 360(9327):103-6. 10.1016/S0140-6736(02)09408-4, 12126818.
3. Al-Mamgani A, van Putten WL, Heemsbergen WD, van Leenders GJ, Slot A, Dielwart MF, Incrocci L, Lebesque JV. Update of dutch multicenter dose-escalation trial of radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 72(4):980-8.
4. Kuban DA, Tucker SL, Dong L, Starkschall G, Huang EH, Cheung MR, Lee AK, Pollack A. Long-term results of the M. D. Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(1):67-74.
5. Zietman AL. Correction: Inaccurate analysis and results in a study of radiation therapy in adenocarcinoma of the prostate. JAMA 2008, 299(8):898-9. 10.1001/jama.299.8.898-c, 18314431.
6. Zietman AL, DeSilvio ML, Slater JD, Rossi CJ, Miller DW, Adams JA, Shipley WU. Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: a randomized controlled trial. JAMA 2005, 294(10):1233-9. 10.1001/jama.294.10.1233, 16160131.
7. Al-Mamgani A, Heemsbergen WD, Peeters ST, Lebesque JV. Role of Intensity-Modulated Radiotherapy in Reducing Toxicity in Dose Escalation for Localized Prostate Cancer. Int J Radiat Oncol Biol Phys 2009, 73(3):685-91.
8. Khoo VS, Norman AR, Syndikus I, Huddart R, Parker C, Eeles R, Horwich A, Dearnaley DP. Randomized pilot study of Conventional or Hypofractionated High dose Intensity modulated Prostate radiotherapy (CHHIP)-acute toxicity report. Prostate Cancer Symposium 2005,
9. Zelefsky MJ, Yamada Y, Kollmeier MA, Shippy AM, Nedelka MA. Long-term outcome following three-dimensional conformal/intensity-modulated external-beam radiotherapy for clinical stage T3 prostate cancer. Eur Urol 2008, 53(6):1172-9. 10.1016/j.eururo.2007.12.030, 18222596.
10. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I. Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. International Journal of Radiation Oncology, Biology, Physics 2002, 53(5):1097-105. 10.1016/S0360-3016(02)02829-8, 12128107.
11. Crook JM, Raymond Y, Salhani D, Yang H, Esche B. Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 1995, 37(1):35-42. 10.1016/0167-8140(95)01613-L, 8539455.
12. Kupelian PA, Langen KM, Willoughby TR, Zeidan OA, Meeks SL. Image-guided radiotherapy for localized prostate cancer: treating a moving target. Semin Radiat Oncol 2008, 18(1):58-66. 10.1016/j.semradonc.2007.09.008, 18082589.
13. Nichol A, Chung P, Lockwood G, Rosewall T, Divanbiegi L, Sweet J, Toi A, Bayley A, Bristow R, Crook J, Gospodarowicz M, McLean M, Milosevic M, Warde P, Catton C. A phase II study of localized prostate cancer treated to 75.6 Gy with 3D conformal radiotherapy. Radiother Oncol 2005, 76(1):11-7. 10.1016/j.radonc.2005.06.002, 15990187.
14. Partin AW, Kattan MW, Subong EN, Walsh PC, Wojno KJ, Oesterling JE, Scardino PT, Pearson JD. Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. JAMA 1997, 277(18):1445-51. 10.1001/jama.277.18.1445, 9145716.
15. Rosewall T, Yan J, Bayley AJ, Kelly V, Pellizzari A, Chung P, Catton CN. Inter-professional variability in the assignment and recording of acute toxicity grade using the RTOG system during prostate radiotherapy. Radiother Oncol 2009, 90(3):395-9. 10.1016/j.radonc.2008.12.003, 19135748.
16. Roach M, Hanks G, Thames H, Schellhammer P, Shipley WU, Sokol GH, Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006, 65(4):965-74.
17. Lukka H, Warde P, Pickles T, Morton G, Brundage M, Souhami L, . Canadian GUROG Controversies in prostate cancer radiotherapy: consensus development. Canadian Journal of Urology 2001, 8(4):1314-22.
18. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 2001, 166(3):876-81. 10.1016/S0022-5347(05)65855-7, 11490237.
19. Cahlon O, Zelefsky MJ, Shippy A, Chan H, Fuks Z, Yamada Y, Hunt M, Greenstein S, Amols H. Ultra-high dose (86.4 Gy) IMRT for localized prostate cancer: toxicity and biochemical outcomes. Int J Radiat Oncol Biol Phys 2008, 71(2):330-7.
20. Brenner DJ, Hall EJ. Fractionation and protraction for radiotherapy of prostate carcinoma. International Journal of Radiation Oncology, Biology, Physics 1999, 43(5):1095-101. 10.1016/S0360-3016(98)00438-6, 10192361.
21. Arcangeli S, Strigari L, Soete G, De Meerleer G, Gomellini S, Fonteyne V, Storme G, Arcangeli G. Clinical and dosimetric predictors of acute toxicity after a 4-week hypofractionated external beam radiotherapy regimen for prostate cancer: results from a multicentric prospective trial. Int J Radiat Oncol Biol Phys 2009, 73(1):39-45.
22. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Hypofractionated intensity-modulated radiotherapy (70 Gy at 2.5 Gy per fraction) for localized prostate cancer: Cleveland Clinic experience. Int J Radiat Oncol Biol Phys 2007, 68(5):1424-30.
23. Lim TS, Cheung PC, Loblaw DA, Morton G, Sixel KE, Pang G, Basran P, Zhang L, Tirona R, Szumacher E, Danjoux C, Choo R, Thomas G. Hypofractionated accelerated radiotherapy using concomitant intensity-modulated radiotherapy boost technique for localized high-risk prostate cancer: acute toxicity results. Int J Radiat Oncol Biol Phys 2008, 72(1):85-92.
24. Martin J, Bristow R, Warde P. Low and intermediate risk prostate cancer-- role of hormonal therapy with external beam radiation therapy. Can J Urol 2006, 13(Suppl 2):63-7.
25. Yassa M, Fortin B, Fortin MA, Lambert C, Van Nguyen T, Bahary JP. Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer. Int J Radiat Oncol Biol Phys 2008, 71(1):58-63.
26. PROFIT - Prostate Fractionated Irradiation Trial. , http://clinicaltrials.gov/ct2/show/NCT00304759
27. Nederveen AJ, Heide UA, Hofman P, Welleweerd H, Lagendijk JJ. Partial boosting of prostate tumours. Radiother Oncol 2001, 61(2):117-26. 10.1016/S0167-8140(01)00405-4, 11690676.
28. Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 2008, 26(28):4563-71. 10.1200/JCO.2007.15.9749, 18645193.
29. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J Clin Oncol 2008, 26(2):242-5. 10.1200/JCO.2007.12.4008, 18182665.
30. de Crevoisier R, Tucker SL, Dong L, Mohan R, Cheung R, Cox JD, Kuban DA. Increased risk of biochemical and local failure in patients with distended rectum on the planning CT for prostate cancer radiotherapy. International Journal of Radiation Oncology, Biology, Physics 2005, 62(4):965-73.
31. Kupelian PA, Willoughby TR, Reddy CA, Klein EA, Mahadevan A. Impact of image guidance on outcomes after external beam radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(4):1146-50.
32. Zelefsky MJ, Levin EJ, Hunt M, Yamada Y, Shippy AM, Jackson A, Amols HI. Incidence of late rectal and urinary toxicities after three-dimensional conformal radiotherapy and intensity-modulated radiotherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2008, 70(4):1124-9.
33. Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, Kudchadker RJ, Thames H, Mohan R, Kuban D. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007, 67(4):1059-65. 2081969, 17241755.
34. Kotte AN, Hofman P, Lagendijk JJ, van Vulpen M, Heide UA.: analysis of 427 patients with implanted fiducial markers. Int J Radiat Oncol Biol Phys 2007, 69(2):therapy419-25.
35. Langen KM, Lu W, Ngwa W, Willoughby TR, Chauhan B, Meeks SL, Kupelian PA, Olivera G. Correlation between dosimetric effect and intrafraction motion during prostate treatments delivered with helical tomotherapy. Phys Med Biol 2008, 53(24):7073-86. 10.1088/0031-9155/53/24/005, 19015580.
36. Li HS, Chetty IJ, Enke CA, Foster RD, Willoughby TR, Kupellian PA, Solberg TD. Dosimetric consequences of intrafraction prostate motion. Int J Radiat Oncol Biol Phys 2008, 71(3):801-12.
37. Parker CC, Damyanovich A, Haycocks T, Haider M, Bayley A, Catton CN. Magnetic resonance imaging in the radiation treatment planning of localized prostate cancer using intra-prostatic fiducial markers for computed tomography co-registration. Radiother Oncol 2003, 66(2):217-24. 10.1016/S0167-8140(02)00407-3, 12648794.
38. Lee I, Sandler H. Hormone therapy and radiotherapy for intermediate risk prostate cancer. Semin Radiat Oncol 2008, 18(1):7-14. 10.1016/j.semradonc.2007.09.002, 18082583.
39. Stephenson AJ, Kattan MW. Nomograms for prostate cancer. BJU Int 2006, 98(1):39-46. 10.1111/j.1464-410X.2006.06173.x, 16831140.
40. Epstein JI, Allsbrook WC, Amin MB, Egevad LL. The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 2005, 29(9):1228-42. 10.1097/01.pas.0000173646.99337.b1, 16096414.